INTERVIEW: I-SPY 2 investigator on cancer study, Synta's ganetespib
This article was originally published in Scrip
The investigator-sponsored I-SPY 2 clinical trial is an ambitious undertaking with a complicated protocol designed to generate data fairly quickly that can predict the chances of Phase III success for breast cancer therapies from various companies.
You may also be interested in...
Seattle Genetics is transitioning from a one-product to multi-product company while growing its established Adcetris franchise. New studies are coming for three additional antibody-drug conjugates aimed at solid tumors.
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.